- Home
- SOPH vs OBIO Comparison
SOPH vs OBIO Comparison
Compare SOPH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | OBIO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 237.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOPH | OBIO |
|---|---|---|
| Price | $4.74 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $14.00 |
| AVG Volume (30 Days) | 103.6K | ★ 271.2K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,297,000.00 | $2,818,000.00 |
| Revenue This Year | $18.32 | $36.43 |
| Revenue Next Year | $15.61 | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.66 | 6.46 |
| 52 Week Low | $2.58 | $2.20 |
| 52 Week High | $5.30 | $6.30 |
Technical Indicators
Market Signals| Indicator | SOPH | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 49.24 |
| Support Level | $4.63 | $4.25 |
| Resistance Level | $4.95 | $4.64 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 28.12 | 15.55 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.